3,3-diethyl-5-methylpiperidine-2,4-dione

• ChemBase编号: 978
• 分子式: C10H17NO2
• 平均质量: 183.24748
• 单一同位素质量: 183.12592879
• SMILES: O=C1C(CC)(CC)C(=O)NCC1C
• Canonical SMILES: CCC1(CC)C(=O)NCC(C1=O)C
• InChI: InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)
• InChIKey: SIDLZWOQUZRBRU-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 3,3-diethyl-5-methylpiperidine-2,4-dione
• IUPAC传统名: dimerin
• 商标名: Dimerin; Noctan; Nodular; Noludar
• 别名: Dea No. 2575; Methyprylon [INN]; Methyprylone [INN-French]; Methyprylonum [INN-Latin]; Methyprolon; Methprylon; Metiprilon; Metiprilona [INN-Spanish]; Metiprilone; Methyprylon

登记号

• CAS号: 125-64-4
• PubChem SID: 160964441; 46506891
• PubChem CID: 4162

理论计算性质

JChem

• Acid pKa: 14.534169
• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): 1.8847077
• LogD (pH = 7.4): 1.8847076
• Log P: 1.8847077
• 摩尔折射率: 50.2501 cm^3
• 极化性: 19.710049 Å^3
• 极化表面积: 46.17 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.94
• LOG S: -1.21
• 溶解度: 1.13e+01 g/l

分子性质

理化性质

• 溶解度: 1.15E+004 mg/L
• 疏水性(logP): 1.2

详细说明

DrugBank - DB01107

• Drug Groups: illicit; approved; withdrawn
• Description: Methyprylon is a sedative of the piperidinedione derivative family. This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with less side effects, such as benzodiazepines. Methyprylon was withdrawn from the US market in June 1965 and the Canadian market in September 1990. [Wikipedia]
• Indication: For the treatment of insomnia.
• Pharmacology: Methyprylon, a piperidinedione CNS depressant, is close to barbituric acid in structure, but different enough to be called a "non-barbiturate" sedative-hynotic. Methyprylon is used for insomnia and daytime tension. Methyprylon depresses the activity of muscle tissues, the heart, and the respiratory system.
• Toxicity: Symptoms of overdose include excitation and convulsions.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Methyprylon is almost completely metabolized.
• Half Life: 6-16 hours
• Protein Binding: 60%
• References: Contos DA, Dixon KF, Guthrie RM, Gerber N, Mays DC: Nonlinear elimination of methyprylon (noludar) in an overdosed patient: correlation of clinical effects with plasma concentration. J Pharm Sci. 1991 Aug;80(8):768-71. [Pubmed] ; Gwilt PR, Pankaskie MC, Thornburg JE, Zustiak R, Shoenthal DR: Pharmacokinetics of methyprylon following a single oral dose. J Pharm Sci. 1985 Sep;74(9):1001-3. [Pubmed] ; Lomen P, Linet OI: Hypnotic efficacy of triazolam and methyprylon ininsomniac in-patients. J Int Med Res. 1976;4(1):55-8. [Pubmed]
• External Links: Wikipedia

参考文献

• Contos DA, Dixon KF, Guthrie RM, Gerber N, Mays DC: Nonlinear elimination of methyprylon (noludar) in an overdosed patient: correlation of clinical effects with plasma concentration. J Pharm Sci. 1991 Aug;80(8):768-71. Pubmed
• Gwilt PR, Pankaskie MC, Thornburg JE, Zustiak R, Shoenthal DR: Pharmacokinetics of methyprylon following a single oral dose. J Pharm Sci. 1985 Sep;74(9):1001-3. Pubmed
• Lomen P, Linet OI: Hypnotic efficacy of triazolam and methyprylon ininsomniac in-patients. J Int Med Res. 1976;4(1):55-8. Pubmed